Acute kidney injury (AKI) is a poorly understood syndrome. AKI has definitions and concepts that are changeable, and it can not rely on the possibility of histological examination for diagnosis, either because of the difficulty in performing a kidney biopsy in critical patients or for its focal nature and its preference for the external layer of the medulla that comprises most of the juxtamedullary glomeruli, which are not frequently obtained. (1) The pathophysiology of AKI has many aspects and depends on many mechanisms involving the endothelium, glycocalyx, cytoskeleton, integrins, lymphokines and chemokines among others. In the most studied experimental animal models of ischemia and reperfusion (1) and even in recent studies of human kidneys from organ donors whose glycocalyces were analyzed in vivo, AKI has inflammatory components and involves neutrophils and macrophages/monocytes. (2) Experimental studies have helped to clarify many aspects of AKI, but it is only possible to evaluate one etiological agent and a small number of mechanisms and outcomes in each study. This limitation is the exact opposite of what happens to patients in which multiple known factors (ischemic or toxic) act in synchrony or chaotically and in which multiple interactions between organs take place. (3) It is possible that the phases of AKI, which are described as prerenal, initiation, extension, maintenance and recovery, do not occur homogeneously in all nephrons. Over times, this syndrome has had multiple definitions (over 30 according to certain reviews) based on serum creatinine levels. (4) Recently, new AKI classification methods (5,6) have been proposed that also use the serum creatinine levels and diuresis but in a manner that is dynamic and standardized. Several drugs have been tested with the objective of preventing and treating AKI, but the promising results obtained in animal studies were not achieved in studies with humans. Is shall be asked if it is possible that the problem with those studies was the diagnosis and severity of disease instead of the treatment tested? It has only recently become understood that that very small increases in serum creatinine (0.3 mg/dL) have an impact on mortality (7) , that the cost associated with these increases is high (8) and that AKI patients can progress to stage 5 chronic kidney disease and become dialysis-dependent (9). However, the implications of the elevated costs implied in treating severe patients by dialysis have been known for a long time and are thoroughly characterized and quantified, suggesting that the quality of life of the survivors is reasonably acceptable, despite the high mortality and cost. (10)